Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
Dyne Therapeutics Inc ownership update: The Vanguard Group filed an amended Schedule 13G/A stating it reports no beneficial ownership of Dyne Therapeutics common stock following an internal realignment. The filing lists Amount beneficially owned: 0 and Percent of class: 0%.
The filing cites an internal realignment effective January 12, 2026 and is signed on 03/26/2026.
Dyne Therapeutics director Brian S. Posner purchased additional shares of the company. On March 11, 2026, he made an open-market purchase of 2,000 shares of Dyne Therapeutics common stock at a price of $19.35 per share. Following this transaction, he directly owns 13,500 shares.
Dyne Therapeutics, Inc. director Dirk Kersten reported an indirect open-market sale of 129,672 shares of common stock at a weighted average price of $19.5151 per share. The sale was executed by ForDyne B.V. under a Rule 10b5-1 trading plan adopted on November 11, 2025.
Following the transaction, ForDyne holds 4,644,386 Dyne Therapeutics shares. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. and Forbion Growth Opportunities Fund II Cooperatief U.A. Kersten disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
Dyne Therapeutics, Inc. director-associated entity ForDyne B.V. reported open-market sales of a total of 688,788 shares of Dyne common stock over March 9–10, 2026. The sales were executed at weighted average prices, with disclosed ranges from $17.50 to $20.03 per share. Following these transactions, entities associated with the reporting person continued to hold 4,774,058 Dyne shares indirectly. The filing notes that the March 2026 sales were made under a pre-arranged Rule 10b5-1 trading plan adopted by ForDyne on November 11, 2025, indicating the trades were scheduled in advance rather than timed discretionarily.
DYN: ForDyne B.V. reported dispositions of Common Stock on 03/09/2026 and 03/10/2026
The filing shows sales of 177,690 shares with proceeds of $3,148,986.64 on 03/09/2026 and 511,098 shares with proceeds of $10,000,336.60 on 03/10/2026.
Dyne Therapeutics, Inc. director Brian S. Posner purchased 3,000 shares of common stock in an open-market transaction. The weighted average purchase price was $15.06 per share, with individual trade prices ranging from $14.96 to $15.12. Following this purchase, he directly owns 11,500 shares.
Dyne Therapeutics, Inc. Chief Commercial Officer Johanna Friedl-Naderer reported an automatic sale of 148 shares of common stock at $14.90 per share. The shares were sold to satisfy tax withholding obligations tied to the vesting of restricted stock units granted on December 4, 2024, under a pre-arranged Rule 10b5-1 "binding contract," so the transaction was not discretionary. After this sale, she beneficially owned 154,581 shares of common stock, including 129,790 unvested RSUs.
Dyne Therapeutics, Inc. Chief Medical Officer Douglas Kerr reported an automatic sale of 904 shares of common stock on March 5, 2026 at $14.90 per share. The shares were sold to satisfy tax withholding obligations tied to the vesting of restricted stock units granted on December 4, 2024, under a pre-arranged Rule 10b5-1 "binding contract," so the transaction was not a discretionary trade. Following this sale, he beneficially owned 171,606 shares, including 153,625 unvested RSUs.